No Data
Enliven Therapeutics: Promising Innovations in Tyrosine Kinase Inhibitors and Strategic Growth Plans Justify Buy Rating
Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $39
Strong Buy Recommendation for Enliven Therapeutics Due to ELVN-001's High Selectivity and Promising Clinical Data
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans
Enliven Therapeutics Insider Sold Shares Worth $685,868, According to a Recent SEC Filing
Insider Sale: CHIEF FINANCIAL OFFICER of $ELVN (ELVN) Sells 900 Shares